Integrated MultImodaL anaLysis for prEdictioN of response after local ablatioN in metastatIc breast cAncer

Integrated MultImodaL anaLysis for prEdictioN of response after local ablatioN in metastatIc breast cAncer - MILLENIA - LMU-RAD01190

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034084

Enrollment

Registered

2024-09-20

Start date

2024-09-16

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50

Interventions

Group 1: To evaluate the immunological, proteomic, , transcriptomic, metabolomic and microbiome profiles in tumor tissues and blood (plasma, serum, leukocytes) as prognostic markers for progression fr

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Availability of tissue and blood samples collected in frame of the ESTIMATE study 2. Diagnosis of metastatic breast cancer

Exclusion criteria

Exclusion criteria: 1. Absence of tissues and blood samples collected in frame of the ESTIMATE study

Design outcomes

Primary

Measure	Time frame
Analysis of primary, metastatic and surrounding tissues stored as FFPE. Analysis of blood (plasma, serum, PBMC, leukocytes) collected before and after local ablation.	—

Secondary

Measure	Time frame
Microbiota analysis of primary, metastatic and surrounding tissues stored as FFPE. Microbiota analysis of blood (plasma, serum, leukocytes) collected before and after local ablation.	—

Countries

Germany

Contacts

Public ContactMarianna Alunni-Fabbroni

Klinik und Poliklinik für Radiologie

Marianna.Alunni@med.uni-muenchen.de+49 89 4400 77605

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026